Background
==========

Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer death worldwide \[[@B1]\]. Mucinous adenocarcinoma (MA) is diagnosed when more than 50% of the tumor comprises a mucinous pattern upon histological examination \[[@B2]\]. MA makes up 6 to 20% of all colorectal cancers \[[@B3]-[@B8]\], and differs from non-mucinous adenocarcinoma (NMA) with regard to its clinicopathological characteristics, distinct genetic profiles, and pathogenic pathways \[[@B9]-[@B12]\].

The prognostic significance of MA is controversial. In previous studies, mucinous histology was reported not to be an independent prognostic factor for survival \[[@B13],[@B14]\]. The guidelines established by the National Comprehensive Cancer Network (NCCN) do not describe mucinous histology as a clinical factor that should influence the therapeutic algorithm \[[@B15],[@B16]\]. However, in some studies, it is reported that MA is associated with worse clinicopathological characteristics \[[@B17]-[@B19]\] and a poorer prognosis than NMA \[[@B5],[@B17],[@B20]-[@B23]\].

The lack of a consensus may be the result of the low ratio of MA to all colorectal cancers and the limited detection power to clarify the differences between MA and NMA.

We conducted a retrospective analysis of patients with colorectal cancer at two major centers to identify the clinicopathological features of MA, and also investigated the recurrence to establish an optimal therapeutic strategy for MA.

Methods
=======

Patients
--------

The data from 2,817 patients with colorectal cancer in two major centers, Kanagawa Cancer Center and Yokohama City University Medical Center, between 2001 and 2010 were investigated. Written informed consent was obtained from the patient for publication of this report and any accompanying images. All patients initially underwent resection of a primary lesion followed by adjuvant chemotherapy when diagnosed as stage III disease. In tumor, node metastases (TNM) stage T3 to T4, lower-rectal cases, total mesorectal excision (TME) and lateral node dissection were routinely performed at initial resection. No patients were treated with neo- or adjuvant radiation therapy.

The analyzed patients were diagnosed with MA, defined as tumors with more than 50% of the tumor volume comprising mucin, or with NMA, defined as tumors without any mucinous features, or with a less than 50% mucinous component \[[@B2]\]. Patients diagnosed with signet ring cell carcinoma, undifferentiated carcinoma, and other histological types were excluded from the analysis.

The covariates included in the study were gender, age, location of the tumor, size of the primary tumor, preoperative serum carcinoembryonic antigen (CEA) level, depth of invasion, lymph node metastasis, distant metastasis, operating facility, and histological type. The pathological tumor status was coded using the TNM classification system \[[@B24]\]. The use of adjuvant chemotherapy for patients with curative resection, as well as additional therapy (chemotherapy and/or surgery) for recurrent and non-curative cases were also recorded.

In the analysis of the survival rates, all cases were divided into 3 groups, that is, patients without any metastases (stage 0 to II \[[@B24]\]), patients with regional lymph node metastasis but without distant metastasis (stage III), and patients with distant metastasis (stage IV).

Statistical analysis
--------------------

The two groups of patients (MA and NMA) were compared using 2 × 2 tables for binary factors using the χ^2^-test, or Fisher's exact test where appropriate. Overall survival was calculated from the date of surgery for the primary lesion until death from any cause, or was censored at the last follow-up visit. Survival data were analyzed using the Kaplan-Meier method. A comparison of survival curves was carried out using the log-rank test. The prognostic significance was analyzed by multivariate Cox proportional hazard models. *P*-values \< 0.05 were considered statistically significant, and all *P*-values correspond to two-sided significance tests.

Results
=======

Of the 2,817 colorectal cancer patients, MA accounted for 5.1% (144) of the colorectal cancer cases. The distribution of the patients' characteristics is shown in Table [1](#T1){ref-type="table"}. The distribution for gender, age, and location of MA was similar to that of NMA. The patients with MA had significantly larger primary lesions, higher preoperative serum CEA levels, deeper invasion, higher nodal and distant metastasis rates, and a larger number of metastatic sites compared to the patients with NMA.

###### 

Comparison of clinicopathological characteristics in non-mucinous and mucinous adenocarcinoma

  **Characteristics**             **NMA**    **MA**   ***P*-value**  
  ------------------------------- --------- -------- --------------- ----------
  Gender                                                               0.772
                                  Female     1,072         56             
                                  Male       1,601         88             
  Age, years                                              0.271      
                                  \< 65      1,183         57             
                                  ≧ 65       1,490         87             
  Location                                                             0.090
                                  Colon      1,516         92             
                                  Rectum     1,157         57             
  Size, cm                                                            \< 0.001
                                  \< 5       1,715         59             
                                  ≥ 5         958          85             
  Preoperative serum CEA, ng/ml                         \< 0.001     
                                  \<5.0      1,858         80             
                                  ≧5.0        815          64             
  Depth of invasion^a^                                  \< 0.001     
                                  T1, T2      979          13             
                                  T3, T4     1,694         131            
  Lymph node metastasis^a^                                0.002      
                                  N0         1,602         68             
                                  N1, N2     1,071         76             
  Distant metastasis^a^                                   0.010      
                                  M0         2,319         114            
                                  M1          354          30             
  Number of metastatic sites                              0.019      
                                  0          2,319         114            
                                  1           269          25             
                                  ≧ 2          86           5             

^a^Staging of tumor (T), nodes (N), and metastases (M) \[[@B24]\]; *NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

Table [2](#T2){ref-type="table"} shows the distribution of treatment factors, including the curability of the first surgery, rate of adjuvant chemotherapy, chemotherapy for advanced or recurrent cases, and additional surgery for liver and lung metastasis. For these factors, there were no significant differences between the MA and NMA groups. Unlike western countries, neo- or adjuvant radiation therapy for patients with stage II and III disease is not commonly performed in Japan.

###### 

Comparison of treatment factors in non-mucinous and mucinous adenocarcinoma

  **Treatment factors**                            **NMA**    **MA**    ***P*-value**
  ---------------------------------------------- ----------- --------- ---------------
  Curability of first surgery                     n = 2,673   n = 144       0.063
     Complete                                       2,411       123            
     Incomplete                                      262        21             
  Curability of first surgery in rectal cancer    n = 1,157   n = 57        0.885
     Complete                                       1,101       54             
     Incomplete                                      56          3             
  Lateral node dissection in rectal cancer        n = 1157    n = 57        0.104
     Yes                                             189        14             
     No                                              968        43             
  Adjuvant chemotherapy                            n = 773    n = 54        0.192
     Yes                                             357        20             
     No                                              416        34             
  Chemotherapy for advanced/recurrent cases        n = 639    n = 55        0.597
     Yes                                             220        17             
     No                                              419        38             
  Additional resection                                                         
  Liver resection for metastatic cases             n = 249    n = 11        0.884
     Yes                                             73          3             
     No                                              176         8             
  Lung resection for metastatic cases              n = 123     n = 5        0.179
     Yes                                             33          0             
     No                                              90          5             

*NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

To clarify the prognostic factors for colorectal cancer, univariate and multivariate analysis were carried out. Mucinous histology was noted to be one of the independent prognostic factors for overall survival in univariate and multivariate analysis (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The 5-year relative survival rate of the MA patients was 52.2%, which was significantly worse than that of the NMA patients (73.8%), with a median follow-up of 52 months (range 1 to 128 months) (Figure [1](#F1){ref-type="fig"}).

###### 

Univariate analysis of overall survival in colorectal adenocarcinoma

  **Variables**                                 **HR (95% CI)**      ***P*-value**
  ------------------------------- ---------- ---------------------- ---------------
  Gender                                                                 0.004
                                  Female              1.0                   
                                  Male        1.349 (1.098, 1.656)          
  Age, years                                                             0.049
                                  \< 65               1.0                   
                                  ≧ 65        1.217 (1.001, 1.480)          
  Location                                                               0.049
                                  Colon               1.0                   
                                  Rectum      1.212 (1.000, 1.468)          
  Size, cm                                                             \< 0.001
                                  \< 5                1.0                   
                                  ≧ 5m        2.432 (2.001, 2.955)          
  Preoperative serum CEA, ng/ml                     \< 0.001        
                                  \< 5.0              1.0                   
                                  ≧ 5.0       3.223 (2.654, 3.915)          
  Depth of invasion^a^                              \< 0.001        
                                  T1, T2              1.0                   
                                  T3, T4      6.122 (4.311, 8.694)          
  Lymph node metastasis^a^                          \< 0.001        
                                  N0                  1.0                   
                                  N1, N2      4.527 (3.972, 5.122)          
  Distant metastasis^a^                             \< 0.001        
                                  M0                  1.0                   
                                  M1          8.133 (6.697, 9.877)          
  Operating facility                                \< 0.001        
                                  Center A            1.0                   
                                  Center B    2.365 (1.943, 2.878)          
  Histological type                                 \< 0.001        
                                  NMA                 1.0                   
                                  MA          2.614 (1.905, 3.585)          

^a^Staging of tumor (T), nodes (N), and metastases (M) \[[@B24]\]; *HR*, hazard ratio; *CI*, confidence interval; *NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

###### 

Multivariate Cox proportional hazards analysis of overall survival in colorectal adenocarcinoma

  **Variables**                                 **HR (95% CI)**      ***P*-value**
  ------------------------------- ---------- ---------------------- ---------------
  Gender                                                                 0.020
                                  Female              1.0                   
                                  Male        1.278 (1.040, 1.572)          
  Age, years                                                             0.007
                                  \< 65               1.0                   
                                  ≧ 65        1.317 (1.078, 1.608)          
  Location                                                               0.020
                                  Colon               1.0                   
                                  Rectum      1.267 (1.038, 1.547)          
  Size, cm                                                               0.112
                                  \< 5                1.0                   
                                  ≧ 5         1.184 (0.961, 1.459)          
  Preoperative serum CEA, ng/ml                     \< 0.001        
                                  \< 5.0              1.0                   
                                  ≧ 5.0       1.483 (1.203, 1.828)          
  Depth of invasion^a^                              \< 0.001        
                                  T1, T2              1.0                   
                                  T3, T4      2.253 (1.534, 3.308)          
  Lymph node metastasis^a^                          \< 0.001        
                                  N0                  1.0                   
                                  N1, N2      2.427 (1.893, 3.105)          
  Distant metastasis^a^                             \< 0.001        
                                  M0                  1.0                   
                                  M1          4.165 (3.350, 5.179)          
  Operating facility                                 0.032          
                                  Center A            1.0                   
                                  Center B    1.192 (1.002, 1.395)          
  Histological type                                 \< 0.001        
                                  NMA                 1.0                   
                                  MA          2.226 (1.618, 3.062)          

^a^Staging of tumor (T), nodes (N), and metastases (M) \[[@B24]\]; *HR*, hazard ratio; *CI*, confidence interval; *NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

![**The 5-year relative survival rate of patients with mucinous adenocarcinoma (52.2%) was significantly worse than those with non-mucinous adenocarcinoma (73.8%) as determined by the log-rank test (*P*** **\< 0.001).** 5yOS, 5-year overall survival.](1477-7819-10-109-1){#F1}

We next divided all cases into 3 groups (stage 0 to II, stage III, and stage IV) to compare the overall survival in each group. There were no significant differences in 5-year survival in stage 0 to II based on the histological status (MA: 88.5% vs. NMA: 91.0%, *P* = 0.099) (Figure [2](#F2){ref-type="fig"}). However, in stage III (MA: 47.3% vs. NMA: 70.5%, *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}) and stage IV (MA: 5.4% vs. NMA: 23.8%, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}), the MA patients had a significantly worse survival rate than the NMA patients.

![The 5-year overall survival of patients with stage I or stage II non-mucinous adenocarcinoma and mucinous adenocarcinoma.](1477-7819-10-109-2){#F2}

![The 5-year overall survival of patients with stage III non-mucinous adenocarcinoma and mucinous adenocarcinoma.](1477-7819-10-109-3){#F3}

![The 5-year overall survival of patients with stage IV non-mucinous adenocarcinoma and mucinous adenocarcinoma.](1477-7819-10-109-4){#F4}

The recurrence pattern in stage III was analyzed (Table [5](#T5){ref-type="table"}). The number of patients with any recurrence in the MA and NMA groups was 17 (31.4%) and 182 (23.5%), respectively. The rate of liver metastasis, distant lymph node metastasis, lung metastasis, and other site recurrence was similar between the two groups. Peritoneal dissemination (7.4% vs. 2.3%, *P* = 0.049), and local recurrence (9.2% vs. 2.3%, *P* = 0.013) were more frequently observed in the MA group. All of the locally recurrent cases in the MA group were rectal cases.

###### 

The comparison of recurrent pattern in patients with stage III disease

  **Recurrent pattern**             **NMA**      **MA**    ***P*-value**
  ------------------------------- ------------ ---------- ---------------
  Liver metastasis                 80 (10.3%)   4 (7.4%)       0.643
  Peritoneal metastasis            18 (2.3%)    4 (7.4%)       0.049
  Distant lymph node metastasis    30 (3.8%)    1 (1.8%)       0.715
  Lung metastasis                  60 (7.7%)    4 (7.4%)       1.000
  Local recurrence                 18 (2.3%)    5 (9.2%)       0.013
  Other site recurrence            16 (2.0%)    3 (5.5%)       0.121

*NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

The treatment factors were compared in stage IV disease (Table [6](#T6){ref-type="table"}). However, the curability of the first resection, first regimen of chemotherapy, and the rate of additional resection did not differ significantly between the MA and NMA groups.

###### 

Comparison of treatment factors in patients with stage IV disease

  **Treatment factors**              **NMA**       **MA**     **P-value**
  ------------------------------- ------------- ------------ -------------
  Curability of first surgery                                    0.353
     Complete                      96 (27.5%)    10 (35.7%)         
     Incomplete                    253 (72.5%)   18 (64.3%)         
  Regimen of first chemotherapy                                  0.362
     OXA-based                      25 (7.1%)    3 (10.7%)          
     IRI-based                      18 (5.1%)    3 (10.7%)          
     5-FU intravenously            43 (12.3%)    4 (14.2%)          
     5-FU orally                   36 (10.3%)    4 (14.2%)          
  Additional resection                                              
     Liver resection               75 (21.4%)    3 (10.7%)       0.228
     Lung resection                 10 (2.8%)     0 (0.0%)       1.000

*OXA*, oxaliplatin; *IRI*, irinotecan; *5-FU*, 5-fluolouracil; *NMA*, non-mucinous adenocarcinoma; *MA*, mucinous adenocarcinoma.

Discussion
==========

In this study, the data from 2,817 colorectal cancer patients who underwent surgery in two major medical centers in Yokohama city, Japan, were analyzed. In these 2,817 patients, the incidence of MA was 5.1%, which generally corresponds to the rate in other Asian countries, as reported by Chew (6.0% from Singapore) \[[@B3]\] and Safaee (8.5% from Iran) \[[@B6]\]. Other studies from Western countries described that the proportion of MA ranged from 11 to 20% \[[@B4],[@B5],[@B7],[@B8]\], which is higher than the rate for Asian countries. This disparity may reflect the differences in geographic, ethnic and dietary factors.

In the analysis of the patients' characteristics, the MA group had worse clinical factors, including larger primary lesions, deeper invasion, higher rates of nodal and distant metastasis, and a larger number of metastatic sites compared to the NMA group. The previous reports showed that younger patients, larger tumors, higher rates of lymph node metastasis, and peritoneal metastasis were correlated with MA histology when compared to NMA histology \[[@B17]-[@B19]\], which was mostly in agreement with our results.

The reason why MA patients have worse characteristics than NMA patients is not fully understood. Sugarbaker *et al*. demonstrated that the more malignant characteristics of MA may be partly due to the production of mucus under pressure, which allows the MA cells to gain access to the peritoneal cavity. Moreover, the fluid produced by MA is taken up by the lymphatic system, which might help to promote tumor spread into regional lymph nodes \[[@B25]\].

It remains unclear whether MA adversely affects survival in colorectal cancer patients. In some studies, MA has been shown to be a significant prognostic factor \[[@B5],[@B17],[@B20]-[@B23]\], while others have found no such evidence \[[@B13],[@B14],[@B26]\]. Both the American Joint Committee on Cancer and the College of American Pathologists consider that the MA subtype has not been proven to be a statistically significant prognostic factor \[[@B14],[@B27]\]. The contradictions in the various studies may be explained by the geographical and racial variations in the epidemiology of colorectal cancer \[[@B28],[@B29]\], disparities in the criteria for defining MA \[[@B22],[@B30]\], and insufficient sample sizes to disclose any differences. In this study, we compared the relative survival rate of MA and NMA patients in a relatively large number of patients, and revealed that the MA patients had significantly worse survival than the NMA patients. Furthermore, multivariate analysis demonstrated that MA histology is an independent prognostic factor.

Based on our findings, we also performed an investigation to establish an optimal therapeutic strategy for MA. To exclude the bias caused by stage, which is related to the status of lymph node metastasis and distant metastasis, we divided all cases into three subgroups and analyzed the relative survival rate in each group. Consequently, the prognosis of patients with MA was similar to that of patients with NMA in stage I/II, whereas it was significantly worse for MA patients in both stage III and stage IV. Some of the above-mentioned literature supports the relatively worse survival of MA patients when the subjects are limited to stage III and stage IV disease \[[@B8],[@B18],[@B21]\], which is consistent with our results. According to these results, we speculated that the worse survival of stage III and IV may contribute to the relatively poor overall prognosis of the MA cases.

In the analysis of the recurrence pattern of stage III disease, the incidence of local recurrence and peritoneal metastasis was significantly higher in patients with MA than in those with NMA. In addition, all cases of local recurrence in the MA group were in patients with rectal disease. Differences in the rates of liver, lung, and distant lymph node metastases were not statistically significant.

In stage IV disease, we compared the treatment factors, including the curability of the first resection, first chemotherapeutic regimen, and the need for additional resection (liver and lung resection). This analysis revealed that equivalent treatments were performed for both MA and NMA patients.

Our results indicate that better management of the local and peritoneal recurrence of stage III disease may improve the survival of MA patients. In terms of local control, previous studies have shown that the difference in survival between MA and NMA patients was mainly related to tumors with a rectal location \[[@B18]\], because MA cases are more likely to be locally recurrent \[[@B31]\], which supports our present results. Green *et al*. pointed out that the lymphatic drainage of the pelvis is more extensive and varied compared with that of the colon \[[@B5]\].

In the NCCN guidelines for treatment of rectal cancer \[[@B16]\], it is recommended to perform pre- or postoperative radiation therapy for patients with T3 to T4, or N1 to N2 disease. However, In Japan, Sugihara *et al*. showed that the five-year overall survival and the five-year locally controlling ratio in patients with T3 to T4 rectal cancer treated by TME plus lateral node dissection, was 79.7% and 92.0% respectively \[[@B32]\]. Consequently, TME and lateral node dissection is considered a standard therapy for T3 to T4 rectal cancer, and neo- or adjuvant radiation therapy is not commonly selected in Japan.

Considering our result, the application of pre- or postoperative radiation therapy \[[@B33]-[@B36]\] may be a strategy to prevent the development of local recurrence in MA cases.

We also found that peritoneal metastasis was a significant site of recurrence for MA in stage III disease. Metastasis to the peritoneum is regarded to be a fatal manifestation of gastrointestinal cancer, and is associated with a median survival time of 5.2 to 12.6 months \[[@B37],[@B38]\]. In terms of the sensitivity to chemotherapy, previous reports have demonstrated that a mucinous histology generally predicts a reduced response to a 5-FU-, oxaliplatin-, and irinotecan-based regimen \[[@B39],[@B40]\].

It is well known that there are several molecular pathways involving oncogene (for example *KRAS*) and the suppressor gene in colorectal carcinogenesis \[[@B41]\], and cetuximab is an established drug used for downstream blocking of the EGFR-KRAS pathway. However, according to Hanski *et al*., MA histology is characterized by a high frequency of *KRAS* mutations, and a high frequency of microsatellite instability \[[@B9]\], suggesting that MA histology generally has drug-resistant properties of cetuximab. It is also revealed that MA has different molecular alterations and genetic subtypes to NMA \[[@B42]\]. Detailed molecular and genetic analyses to detect specific pathways of MA will help to develop new systemic chemotherapy, which is necessary to improve peritoneal metastasis and overall survival in patients with MA.

Conclusion
==========

Our study indentified MA histology as an independent prognostic factor, and revealed that MA was associated with worse survival compared with NMA in patients with stage III and IV disease. The ability of MA to disseminate and infiltrate more aggressively than NMA appears to be responsible, at least in part, for the higher rate of failure in stage III and IV, which are the main reasons for the overall poorer prognosis of patients with MA. Controlling local recurrence and managing peritoneal metastasis are necessary to improve the overall survival in patients with MA.

Besides considering radiation therapy after TME and radical lymph node dissection for locally advanced rectal cases, further investigations focusing on the genetic and molecular characteristics of MA, will help better management of MA histology.
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